Ranexa Angina Reduction Enough For Restricted Indication, CVT Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A mean weekly reduction of 0.4 angina attacks seen in the ERICA study with CV Therapeutics' Ranexa (ranolazine) is adequate for approval, the company said, despite being less than half the expected decrease